Print Email Facebook Twitter Leflunomide and methotrexate reduce levels of activated matrix metalloproteinases in complexes with α2 macroglobulin in serum of rheumatoid arthritis patients Title Leflunomide and methotrexate reduce levels of activated matrix metalloproteinases in complexes with α2 macroglobulin in serum of rheumatoid arthritis patients Author Tchetverikov, I. Kraan, M.C. van El, B. Hanemaaijer, R. de Groot, J. Huizinga, T.W.J. Publication year 2008 Abstract Objective: To analyse the effects of leflunomide and methotrexate treatment on matrix metalloproteinase (MMP) activity levels in a2 macroglobulin/MMP (α2M/MMP) complexes in the systemic circulation of rheumatoid arthritis (RA) patients. Methods: A total of 102 RA patients from a prospective, double-blind, randomised clinical trial comparing leflunomide and methotrexate were selected; clinical data and blood samples were collected at baseline, at 4 months and at 1 year. Serum MMP activity levels in α2M were quantified using low molecular weight fluorogenic substrates, indicating the proportion of activated MMPs that were not inhibited by specific tissue inhibitors of MMP (TIMP). Results: Patients had active disease as shown by high disease activity score (DAS, mean of 6.9 and 7.0 for methotrexate and leflunomide patients respectively), which was reduced over the study period (4.2 and 5.2 respectively, p<0.001). In leflunomide-treated patients a significant reduction of MMP activity levels was observed as early as at the 4 months timepoint persisting thereafter, whereas in methotrexate-treated patients the reduction was seen at 1 year. Conclusion: The results show that systemic levels of activated MMPs are reduced in RA patients upon exposure to leflunomide or methotrexate. Chemicals / CAS: alpha 2 macroglobulin, 95568-41-5; C reactive protein, 9007-41-4; leflunomide, 75706-12-6; methotrexate, 15475-56-6, 59-05-2, 7413-34-5; teriflunomide, 108605-62-5, 282716-73-8; tissue inhibitor of metalloproteinase 1, 140208-24-8; alpha-Macroglobulins; Antirheumatic Agents; batimastat, 130370-60-4; Biological Markers; C-Reactive Protein, 9007-41-4; Enzyme Inhibitors; Isoxazoles; leflunomide, 75706-12-6; Matrix Metalloproteinases, EC 3.4.24.-; Methotrexate, 59-05-2; Multiprotein Complexes; Phenylalanine, 63-91-2; Thiophenes Subject BiologyBiomedical Researchalpha 2 macroglobulinC reactive proteinleflunomidematrix metalloproteinasemethotrexateteriflunomidetissue inhibitor of metalloproteinase 1analysisblood samplingclinical studycomplex formationcontrolled studydisease activitydrug activitydrug dose increasedrug effectdrug efficacydrug exposureloading drug dosemajor clinical studypriority journalprotein blood levelquantitative analysisrheumatoid arthritisserumsystemic circulationAgedalpha-MacroglobulinsAntirheumatic AgentsArthritis, RheumatoidBiological MarkersC-Reactive ProteinDown-RegulationEnzyme InhibitorsFemaleHumansIsoxazolesMaleMatrix MetalloproteinasesMethotrexateMiddle AgedMultiprotein ComplexesPhenylalanineStatistics, NonparametricThiophenes To reference this document use: http://resolver.tudelft.nl/uuid:5600f049-2bd1-45b0-8f92-599f932454f4 DOI https://doi.org/10.1136/ard.2006.067827 TNO identifier 240571 ISSN 0003-4967 Source Annals of the Rheumatic Diseases, 67 (1), 128-130 Document type article Files To receive the publication files, please send an e-mail request to TNO Library.